Literature DB >> 24335852

Increased susceptibility to cortical spreading depression in an animal model of medication-overuse headache.

A Laine Green1, Pengfei Gu1, Milena De Felice1, David Dodick2, Michael H Ossipov1, Frank Porreca3.   

Abstract

OBJECTIVE: The objective of this article is to evaluate electrically evoked thresholds for cortical spreading depression (CSD) and stress-induced activation of trigeminal afferents in a rat model of medication-overuse headache (MOH).
METHODS: Sumatriptan or saline was delivered subcutaneously by osmotic minipump for six days to Sprague-Dawley rats. Two weeks after pump removal, animals were anesthetized and recording/stimulating electrodes implanted. The animals were pretreated with vehicle or topiramate followed by graded electrical stimulation within the visual cortex. CSD events were identified by decreased EEG amplitude and DC potential shift. Additional unanesthetized sumatriptan or saline-pretreated rats were exposed to bright light environmental stress and periorbital and hindpaw withdrawal thresholds were measured. Following CSD stimulation or environmental stress, immunohistochemical staining for Fos in the trigeminal nucleus caudalis (TNC) was performed.
RESULTS: Sumatriptan pre-exposure significantly decreased electrical stimulation threshold to generate a CSD event. Topiramate normalized the decreased CSD threshold as well as stress-induced behavioral withdrawal thresholds in sumatriptan-treated rats compared to saline-treated animals. Moreover, CSD and environmental stress increased Fos expression in the TNC of sumatriptan-treated rats, and these effects were blocked by topiramate. Environmental stress did not elicit cutaneous allodynia or elevate TNC Fos expression in saline-treated rats.
CONCLUSIONS: A previous period of sumatriptan exposure produced long-lasting increased susceptibility to evoked CSD and environmental stress-induced activation of the TNC that was prevented by topiramate. Lowered CSD threshold, and enhanced consequences of CSD events (increased activation of TNC), may represent an underlying biological mechanism of MOH related to triptans. © International Headache Society 2013 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav.

Entities:  

Keywords:  Fos; Migraine; TNC; cortical spreading depression (CSD); medication-overuse headache (MOH); topiramate; triptans

Mesh:

Substances:

Year:  2013        PMID: 24335852      PMCID: PMC4103974          DOI: 10.1177/0333102413515344

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  70 in total

Review 1.  Physiology and neurobiology of stress and adaptation: central role of the brain.

Authors:  Bruce S McEwen
Journal:  Physiol Rev       Date:  2007-07       Impact factor: 37.312

2.  New appendix criteria open for a broader concept of chronic migraine.

Authors:  J Olesen; M-G Bousser; H-C Diener; D Dodick; M First; P J Goadsby; H Göbel; M J A Lainez; J W Lance; R B Lipton; G Nappi; F Sakai; J Schoenen; S D Silberstein; T J Steiner
Journal:  Cephalalgia       Date:  2006-06       Impact factor: 6.292

Review 3.  Pathophysiology of medication overuse headache: insights and hypotheses from preclinical studies.

Authors:  Ian D Meng; David Dodick; Michael H Ossipov; Frank Porreca
Journal:  Cephalalgia       Date:  2011-03-28       Impact factor: 6.292

4.  Efficient analysis of experimental observations.

Authors:  W J Dixon
Journal:  Annu Rev Pharmacol Toxicol       Date:  1980       Impact factor: 13.820

5.  Overuse of symptomatic medications among chronic (transformed) migraine patients: profile of drug consumption.

Authors:  Abouch Valenty Krymchantowski
Journal:  Arq Neuropsiquiatr       Date:  2003-04-16       Impact factor: 1.420

6.  Topiramate in the treatment of migraine: a kainate (glutamate) receptor antagonist within the trigeminothalamic pathway.

Authors:  Anna P Andreou; Peter J Goadsby
Journal:  Cephalalgia       Date:  2011-09-05       Impact factor: 6.292

Review 7.  [Stress and migraine].

Authors:  F Radat
Journal:  Rev Neurol (Paris)       Date:  2013-04-19       Impact factor: 2.607

8.  Cortical spreading depression-new insights and persistent questions.

Authors:  A Charles; Kc Brennan
Journal:  Cephalalgia       Date:  2009-10       Impact factor: 6.292

9.  Focal hyperemia followed by spreading oligemia and impaired activation of rCBF in classic migraine.

Authors:  J Olesen; B Larsen; M Lauritzen
Journal:  Ann Neurol       Date:  1981-04       Impact factor: 10.422

Review 10.  Overuse of acute migraine medications and migraine chronification.

Authors:  Marcelo E Bigal; Richard B Lipton
Journal:  Curr Pain Headache Rep       Date:  2009-08
View more
  19 in total

1.  The effects of acute and preventive migraine therapies in a mouse model of chronic migraine.

Authors:  Alycia F Tipton; Igal Tarash; Brenna McGuire; Andrew Charles; Amynah A Pradhan
Journal:  Cephalalgia       Date:  2016-07-19       Impact factor: 6.292

Review 2.  A critical evaluation of validity and utility of translational imaging in pain and analgesia: Utilizing functional imaging to enhance the process.

Authors:  Jaymin Upadhyay; Christian Geber; Richard Hargreaves; Frank Birklein; David Borsook
Journal:  Neurosci Biobehav Rev       Date:  2017-08-12       Impact factor: 8.989

Review 3.  Medication-overuse headache: a perspective review.

Authors:  Maria Lurenda Westergaard; Signe Bruun Munksgaard; Lars Bendtsen; Rigmor Højland Jensen
Journal:  Ther Adv Drug Saf       Date:  2016-06-30

4.  Systematic review of the pharmacological agents that have been tested against spreading depolarizations.

Authors:  Anna Klass; Renan Sánchez-Porras; Edgar Santos
Journal:  J Cereb Blood Flow Metab       Date:  2018-04-20       Impact factor: 6.200

5.  Kappa opioid receptor antagonists: A possible new class of therapeutics for migraine prevention.

Authors:  Jennifer Y Xie; Milena De Felice; Caroline M Kopruszinski; Nathan Eyde; Justin LaVigne; Bethany Remeniuk; Pablo Hernandez; Xu Yue; Naomi Goshima; Michael Ossipov; Tamara King; John M Streicher; Edita Navratilova; David Dodick; Hugh Rosen; Ed Roberts; Frank Porreca
Journal:  Cephalalgia       Date:  2017-04-04       Impact factor: 6.292

6.  Triptans disrupt brain networks and promote stress-induced CSD-like responses in cortical and subcortical areas.

Authors:  L Becerra; J Bishop; G Barmettler; Y Xie; E Navratilova; F Porreca; D Borsook
Journal:  J Neurophysiol       Date:  2015-10-21       Impact factor: 2.714

Review 7.  Animal Models of Chronic Migraine.

Authors:  Tse-Ming Chou; Shih-Pin Chen
Journal:  Curr Pain Headache Rep       Date:  2018-05-19

Review 8.  Chronic migraine: risk factors, mechanisms and treatment.

Authors:  Arne May; Laura H Schulte
Journal:  Nat Rev Neurol       Date:  2016-07-08       Impact factor: 42.937

Review 9.  The Evolution of Medication Overuse Headache: History, Pathophysiology and Clinical Update.

Authors:  Christina Sun-Edelstein; Alan M Rapoport; Wanakorn Rattanawong; Anan Srikiatkhachorn
Journal:  CNS Drugs       Date:  2021-05-17       Impact factor: 5.749

10.  Gi-protein-coupled 5-HT1B/D receptor agonist sumatriptan induces type I hyperalgesic priming.

Authors:  Dioneia Araldi; Luiz F Ferrari; Jon D Levine
Journal:  Pain       Date:  2016-08       Impact factor: 7.926

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.